Vimarsana
Biggest News Aggregation in the World

Page 9 - Pharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Inc Today - Breaking & Trending Today

HC Wainwright Lowers Hookipa Pharma (NASDAQ:HOOK) Price Target to $5.00 - Vimarsana News

HC Wainwright Lowers Hookipa Pharma (NASDAQ:HOOK) Price Target to $5.00

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its price target lowered by research analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada restated an “outperform” rating and […]

Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views - HOOKIPA Pharma (NASDAQ:HOOK) - Vimarsana News

Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views - HOOKIPA Pharma (NASDAQ:HOOK)

Hookipa Pharma (NASDAQ:HOOK) Price Target Cut to $5.00 - Vimarsana News

Hookipa Pharma (NASDAQ:HOOK) Price Target Cut to $5.00

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its target price decreased by investment analysts at HC Wainwright from $6.50 to $5.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Separately, Royal Bank of Canada reaffirmed an “outperform” rating and […]

Lantern Pharma (NASDAQ:LTRN) Receives "Neutral" Rating from HC Wainwright - Vimarsana News

Lantern Pharma (NASDAQ:LTRN) Receives "Neutral" Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Lantern Pharma (NASDAQ:LTRN – Free Report) in a research note published on Thursday morning, Benzinga reports. Lantern Pharma Stock Performance Shares of NASDAQ LTRN opened at $5.46 on Thursday. Lantern Pharma has a 12 month low of $2.38 and a 12 month high of $11.99. The […]

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for - Vimarsana News

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for

Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or...